Book Chapter

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

Fabio Nicolini¹, Martine Bocchini¹, Giuseppe Bronte², Angelo Delmonte², Massimo Guidoboni³, Lucio Crinò² and Massimiliano Mazza¹*

¹Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy
²Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy
³Immunotherapy and Cell Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

*Corresponding Author: Massimiliano Mazza, Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Published January 11, 2021

This Book Chapter is a republication of an article published by Massimiliano Mazza, et al. at Frontiers in Oncology in January 2020. (Nicolini F, Bocchini M, Bronte G, Delmonte A, Guidoboni M, Crinò L and Mazza M (2020) Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. Front. Oncol. 9:1519. doi: 10.3389/fonc.2019.01519)

How to cite this book chapter: Fabio Nicolini, Martine Bocchini, Giuseppe Bronte, Angelo Delmonte, Massimo Guidoboni, Lucio Crinò, Massimiliano Mazza. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. In: Heidari A, editor. Prime Archives in Cancer Research. Hyderabad, India: Vide Leaf. 2021.
Abstract

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the pleural surface associated with asbestos exposure. The median survival of MPM patients is a mere 8–14 months, and there are few biomarkers and no cure available. It is hoped that, eventually, the incidence of MPM will drop and remain low and constant, given that most nations have banned the use of asbestos, but in the meantime, the incidence in Europe is still growing. The exact molecular mechanisms that explain the
carcinogenicity of asbestos are not known. Standard therapeutic strategies for MPM include surgery, often coupled with chemotherapy and/or radiotherapy, in a small percentage of eligible patients and chemotherapy in tumors considered unresectable with or without adjuvant radiotherapy. In recent years, several new therapeutic avenues are being explored. These include angiogenesis inhibitors, synthetic lethal treatment, miRNA replacement, oncoviral therapies, and the fast-growing field of immunotherapy alone or in combination with chemotherapy. Of particular promise are the multiple options offered by immunotherapy: immune checkpoint inhibitors, tumor vaccines, and therapies taking advantage of tumor-specific antigens, such as specific therapeutic antibodies or advanced cell-based therapies exemplified by the CAR-T cells. This review comprehensively presents both old and new therapeutic options in MPM, focusing on the results of the numerous recent and on-going clinical trials in the field, including the latest data presented at international meetings (AACR, ASCO, and ESMO) this year, and concludes that more work has to be done in the framework of tailored therapies to identify reliable targets and novel biomarkers to impact MPM management.

**Keywords**

Malignant Pleural Mesothelioma (MPM); Immunotherapy; Mesothelin; CAR (Chimeric Antigen Receptor) T Cells; miRNA Replacement

**Introduction**

Malignant pleural mesothelioma (MPM) is a rare, incurable, aggressive cancer of the pleural surface associated with asbestos exposure with a median survival of 8–14 months [1,2]. Although the incidence in some countries, e.g., the USA (3,200 cases/year) [3], is fairly constant, in Europe, it is growing and is expected to peak between 2020 and 2025 [1]. Moreover, the migratory phenomena toward western countries from nations lacking legislation on asbestos use will render MPM even more frequent. At present, no actionable driver mutations have been identified in MPM. However, MPM carcinogenesis and outcome are
influenced by many factors: BRCA-associated protein 1 (BAP1) expression status, CDKN2A and neurofibromatosis type 2 (NF2) tumor suppressor inactivation, overexpression of growth factors such as vascular endothelial growth factor (VEGF), mesothelin (MSLN) promoter methylation, and Ras/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/mTOR pathway activation [4,5].

**Mesothelioma Therapies**

**Standard**

The standard therapeutic strategies for MPM are (i) surgery for resectable tumors, often combined with radiotherapy (RT) and/or chemotherapy (CT) (trimodality treatment), and (ii) CT or RT in unresectable tumor cases. To date, the only FDA- and EMA-approved frontline therapy is the cisplatin-pemetrexed combination [6–10]. Only selected patients can benefit from a complete resection, either lung-sacrificing surgery (extrapleural pneumonectomy, EPP) or lung-sparing (pleurectomy/decortication, P/D) [11–13]. Surgery can be coupled with intraoperative treatments [14–17], but a general consensus on the proper multimodality approach is lacking.

**Radiotherapy**

RT is used as an adjuvant or neoadjuvant treatment in MPM, mainly in a palliative setting [8–10]. As standard practice, patients undergoing an EPP receive adjuvant conventionally fractionated RT (50–60 Gy) in the ipsilateral hemithorax area [18,19]. In node-negative MPM patients, neoadjuvant therapy, based on intensity-modulated RT (IMRT) consisting of a fractionated irradiation of 5–6 Gy, is delivered before EPP [20–22]. In contrast, prophylactic radiotherapy of chest wall tracts after surgery to prevent parietal tumor seeding is not recommended anymore by the ASCO guidelines following the results of the SMART and PIT trials [23–25]. Recently, adjuvant hemithoracic pleural RT has been shown to be effective and safe [26–28]. Advanced RT treatments, e.g., proton therapy [29] or Arc therapy (a novel and accurate IMRT modality) [30], alone or
combined with immunotherapies, are being tested to improve RT impact in MPM management.

**Angiogenesis Inhibitors**

The angiogenic process plays an important role in MPM maintenance. VEGF receptor tyrosine kinase inhibitor (TKI) monotherapy yielded modest results [31–37]. The addition of bevacizumab, a humanized monoclonal antibody against VEGF, to cisplatin-pemetrexed CT increases the median overall survival (OS) from 16.1 to 18.8 months and progression-free survival (PFS) from 7.3 to 9.2 months, as shown in the phase III MAPS study (NCT00651456) [38]. Since this therapeutic regimen showed manageable toxicities, it has been included in the National Comprehensive Cancer Network guidelines (category 2A) [39], although it is not yet approved by the FDA or EMA. The SWOG S0905 phase I study evaluated the combination of cisplatin-pemetrexed CT with cediranib, a VEGF/PDGF receptor inhibitor, demonstrating a preliminary promising efficacy and reasonable toxicity profile [40] but, when compared to placebo, this combination failed to significantly increase OS and PFS in the following randomized phase II trial [41]. Nintedanib is an inhibitor of three (triplet regimen) different growth factor receptors (VEGFR, PDGFR, and FGFR) and its administration in combination with CT improved the objective response rate (ORR) from 44 to 57% and the median PFS (9.7 vs. 5.7 months) compared to placebo in the LUME-Meso trial [42]. Data from the phase III LUME-Meso trial (NCT01907100) have recently been published, and the primary PFS endpoint failed, not confirming the previous phase II trial results [43]. Other TKIs, such as the anti-VEGFR axitinib [44] or the multi-target inhibitor of VEGFR1/2/3, FGFR-1, PDGFR-β, and RAF/cKit pathway sorafenib failed to improve median OS and PFS in chemonaive or CT-pretreated MPM patients [45,46]. The limited success of anti-angiogenic drugs is due to the lack of good predictive biomarkers to guide the selection of suitable patients for this therapy. Recently, blocking of FGF signaling has been pursued through the sequestration of FGFs with the GSK3052230 ligand trap molecule to avoid toxicities associated with FGFR inhibitors. A phase Ib study indicates that a
combination of GSK3052230 plus cisplatin-pemetrexed-CT leads to an ORR of 44% and to a median PFS of 7.4 months with limited adverse events [47].

**Synthetic Lethal Therapies**

Some MPM tumors cannot synthesize arginine due to the loss of argininosuccinate synthetase 1 (ASS1) gene expression. ASS1 deficiency is twice more frequent in the biphasic/sarcomatoid histotypes than in the epithelioid subtype. In vitro experiments suggest that depletion of arginine through exposure to a specific deaminase leads to synthetic lethality [48]. The TRAP phase I trial (NCT02029690) demonstrated a positive effect of treatment with pegylated arginine deaminase (ADI-PEG 20) combined with CT in ASS1-deficient MPM patients [49]. The ATOMIC-Meso phase III trial (NCT02709512) is recruiting patients with ASS1 gene loss. Genomic studies on MPM cells reported a reduced or absent expression of an enzyme involved in DNA repair and Ca^{2+}-dependent apoptosis BAP1 in ~50% of sporadic MPMs. In vitro studies demonstrated that BAP1-mutated cells are less sensitive to ionizing radiation causing DNA double-strand breaks [50,51] or to the DNA synthesis inhibitor gemcitabine [52], highlighting the contribution of BAP1 in DNA damage signaling and repair and a possible role as a predictive biomarker [53]. Inherited loss-of-function mutations in BAP1 predispose to multiple carcinomas, including mesothelioma [54–56]. Interestingly, MPM patients with germline mutated BAP1 or with genetic alterations in other DNA repair genes and treated with platinum CT showed a significantly longer median OS than patients devoid of the same mutations [57]. Hence the BAP1 mutational status at diagnosis could be an important factor in predicting MPM patients' response to CT and may sensitize patients to synthetic lethality therapies that hit other components of the DNA repair machinery. Accordingly, as already suggested by Srinivasan et al. [58], the homologous repair (HR) component PARP-1 would be an excellent target for a synthetic lethality approach, given that MPM cells are frequently characterized by HR deficiency and unrepaired DNA damage accumulation due to the aforementioned BAP1 mutations. PARP-1 inhibitors, such as niraparib and olaparib, clearly decreased MPM cell survival,
albeit regardless of BAP1 status. BAP1 loss also up-regulates the expression of EZH2, a Polycomb Repressive Complex-2 (PRC2) component involved in epigenetic silencing [59] and oncogenic pathways [60], suggesting sensitivity of BAP1-deficient MPM tumors to EZH2 inhibition. A phase II clinical trial (NCT02860286) is ongoing to evaluate the efficacy of the EZH2 inhibitor tazemetostat in MPM patients [61].

Finally, the synthetic lethality of inhibition of the Focal Adhesion Kinase (FAK) tyrosine kinase with loss of Merlin protein, the first involved in the survival, proliferation, and migration of tumor cells [62] and the second, a tumor suppressor encoded by the NF2 gene frequently mutated in MPM [5], has been proposed. Despite an encouraging positive trend observed in phase I trial in which FAK inhibitor GSK2256098 was tested in MERLIN-negative patients [63], a second large phase II trial (COMMAND, NCT01870609) demonstrated that neither PFS nor OS was improved by the FAK TKI defactinib as compared to placebo when administered as a maintenance treatment after frontline CT [64].

**Immunotherapies**

Multiple lines of evidence point to the involvement of the immune system in the pathogenesis and sensitivity to therapy of MPM [65,66]. Spontaneous regressions in some patients are attributable to an activation of the immune system [67,68]. Moreover, B cells are essential for a good prognosis [69] in murine preclinical models of mesothelioma treated with immunotherapy, indicating that antibodies are generated and contribute to the therapeutic effect. Also, the presence of cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) is a good prognostic marker in MPM [70,71].

MPM can be immunogenic but develops mechanisms to evade immune eradication. PD-L1 is the ligand for PD-1, a receptor expressed by activated T and B cells. Binding of PD-L1 to PD-1 affects effector T-cell and B-cell function and ultimately leads to exhaustion and apoptosis [72]. Recently PD-L1 was shown to be expressed in 40% of MPMs, almost all of the sarcomatoid
subtype, and was associated with a significantly poorer outcome, with a median survival of 5 months for PD-L1+ MPM patients vs. 14.5 months for PD-L1− tumors ($p < 0.0001$) [73]. However, PD-L1 expression is heterogeneous among MPM cells and could vary during treatment, limiting the efficacy of anti-PD-(L)1 therapy [74,75].

**Immune Checkpoint Inhibitors**

Immune checkpoint inhibitors (ICIs) are immune-modulating agents that boost the latent immune-response kept in check by the tumor. PD-1/PD-L1 and CTLA-4 inhibitory functions are targeted by immunomodulatory therapies, allowing T- and B-cell (re-)activation [76]. Recently, many ICIs, including anti-CTLA-4, a glycoprotein expressed on regulatory and on activated CD4+ and CD8+ T cells, or anti-programmed death 1 (PD-1)/PD-L1 antibodies, have been approved for the treatment of solid and hematological malignancies [76–78].

Despite early enthusiasm for the results of tremelimumab, an anti-CTLA-4 ICI, as first-line therapy [79], its use as a second- or third-line treatment demonstrated no benefit of CTLA-4 inhibition over placebo (DETERMINE, NCT01843374) [80]. Nivolumab efficacy was tested as a second- or third-line treatment alone vs. placebo in MPM patients in two recently completed phase II studies (NivoMes, NCT02497508, and MERIT, JapicCTI-163247) with ORRs of 24.0 and 29.4% and disease control rates (DCRs) of 50.0 and 67.6%, respectively [81,82]. A clear correlation between response and PD-L1 expression was reported [81]. An ongoing randomized, placebo-controlled phase III trial is testing the efficacy of nivolumab in relapsed mesothelioma (CONFIRM, NCT03063450) [83].

The anti-PD-1 ICI pembrolizumab has been evaluated in different phase I (KEYNOTE-028, NCT02054806) and II (NCT02399371) studies as a second- or third-line treatment, showing promising DCR and prolonged disease stability [84–86]. The results from the randomized phase III trial PROMISE-meso (NCT02991482) were instead disappointing, with relapsed MPM patients receiving pembrolizumab or single-agent CT
failing to show an improved median OS and PFS despite a superior ORR for pembrolizumab compared to a CT regimen (22 vs. 6%) [87]. Popat and colleagues suggest that ICI treatment should be tested at earlier stages and on patients that are better stratified to benefit from longer periods of immunotherapy.

Other ICIs, like the Inducible T-cell COStimulator (ICOS) agonist GSK3359609, alone or in combination with pembrolizumab, are being evaluated in advanced solid tumors including MPM (INDUCE-I, NCT02723955) [88].

**Combination Strategy**

Two ICIs against different targets can be combined. An ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) combination was tested in the phase-II MAPS2 trial [89] in relapsed MPM patients. The results indicated that the primary endpoint, DCR after 12 weeks, was reached by combined therapy (50%) and not by nivolumab alone (44%). An ORR of 25.9 vs. 18.5% and a modest increase of median response duration (7.4 vs. 7.9 months) were achieved in the combination and nivolumab groups, respectively. Severe treatment-related side effects were registered in 17% of patients. The same combination is being investigated in a randomized phase III trial (Checkmate 743, NCT02899299) in the front-line setting [90]. Similarly, the combined therapy of tremelimumab plus durvalumab, an anti-PD-L1 antibody, tested in the phase II NIBUT-MESO-1 trial (NCT02588131), resulted in grade 3–4 treatment-related side effects in 17.5% of patients [91]. A phase III study is evaluating the combination of pembrolizumab with pemetrexed and platinum-based CT vs. pembrolizumab or CT alone as first-line treatment for MPM patients (NCT02784171).

**Innovative Therapeutic Approaches for Malignant Mesothelioma**

**miRNA Replacement**

miRNA replacement is an innovative anti-cancer approach that restores miRNA expression by delivering miRNAs or miRNA mimics. Restored miRNAs can interfere with the expression of
proteins endowed with oncogenic activity [92–94] thereby inhibiting proliferation or inducing apoptosis of tumor cells [95].

miR-16 is often downregulated in MPM, while its expression in in vitro and in murine xenografts results in decreased cell proliferation, decreased glucose uptake, and increased mortality [95]. The feasibility of miR-16 exploitation by delivering its mimic encapsulated into an anti-EGFR-coated bacterially-derived shell termed EnGeneIC Dream Vector (TargomiR) [96] was shown in the NCT02369198 trial, which reported efficacy and good tolerability in patients with relapsed MPM [97]. TargomiR therapy was associated with a drop in glucose uptake in 60% of patients as measured by PET-CT, while 73% of patients achieved disease control.

**Tumor Treating Fields**

Recently, the FDA approved an innovative first-line treatment for MPM patients as a humanitarian use device, called NovoTTF-100L, that is based on the delivery of specific electric frequencies (Tumor Treating Fields, TTF) in combination with CT, to interfere with cancer cell proliferation. In vitro and in vivo data [98] are consistent with recent STELLAR phase II registration trial (NCT02397928) results, where a median OS of 18.2 months and low systemic toxicity have been experienced by the patients treated with TTF plus CT [99].

**Oncoviral Therapies**

In the wake of successful phase I and II studies [100,101], a phase III clinical trial (INFINITE, NCT03710876) is evaluating the efficacy of an Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with celecoxib and gemcitabine in MPM patients who failed previous regimens. A phase II study (NCT04013334) is testing the efficacy of Ad-SGE-REIC/MTG201, an adenooviral vector for the expression of Reduced Expression in Immortalized Cell (REIC)/Dickkopf-3 (Dkk-3) gene in combination with nivolumab. The Dkk-3 protein is a Wnt signaling pathway antagonist that induces cancer cell death and antitumor immune response. A previous phase I/II
study showed that intrapleural virus administration was safe and well-tolerated and that Dkk-3 gene expression allowed durable disease control [102]. Preclinical studies evaluated the replication-competent neuroattenuated Herpex Simplex Virus (HSV-1716) as oncolytic virotherapy for mesothelioma, showing cytotoxicity in combination with CT or RT in vitro and reduced tumor growth also at low doses in vivo in MPM murine models [103]. The results of a phase I/IIa trial (NCT01721018) testing the intrapleural administration of HSV-1716 demonstrated virus replication, pleural Th1 cytokine response, and anti-tumor immunoglobulin production [104]. The use of other viral vectors [reviewed in [105]], such as attenuated versions of vaccinia or measles virus genetically engineered to produce human thyroidal sodium iodine symporter (NIS), is being investigated in different phase I clinical trials (NCT02714374, NCT01503177).

**Dendritic Cell Vaccination**

Cancer vaccines aim at inducing tumor-specific effector T cells that reduce tumor mass and induce tumor-specific memory T cells to curtail tumor relapse [106]. Autologous dendritic cell vaccination (DCV) has shown efficacy in MPM treatment. The PMR-MM-002 clinical trial (NCT01241682) demonstrated the safety and feasibility of tumor lysate-pulsed dendritic cells as therapeutic adjuvants in MPM patients [107]. The DENIM phase II/III randomized clinical trial (NCT03610360) will treat MPM patients with dendritic cell immunotherapy plus best supportive care (BSC) and compare the results with BSC alone [108]. Other vaccination-based therapies currently under investigation are autologous DC loaded with Wilms' Tumor Antigen (WT1) [109] combined with CT (MESODEC, NCT02649829) and autologous TILs plus IL-2 [110]. Based on the results obtained by PMR-MM-002 and by ICIs, a phase Ib MESOVAX clinical trial (NCT03546426) is recruiting MPM patients to test the efficacy of a tandem combination of autologous DCV and pembrolizumab at our institute.
Mesothelioma Targeting Antigens

MSLN is a glycoprotein expressed more on the cell surface of several tumors, including MPM cells, than in normal tissues [111]. A phase II clinical trial (NCT00738582) testing amatuximab, a chimeric anti-MSLN mAb, plus standard CT compared to CT alone showed a promising OS of 14.8 months [112] that was not confirmed in the ARTEMIS trial (NCT02357147). Anetumab raptansine (AR), an anti-MSLN antibody conjugated with the cytotoxic anti-tubulin drug raptansine, showed a 50% ORR and 90% DCR in pretreated patients [113]. A second phase II randomized clinical trial showed that AR did not improve survival compared to the anti-mitotic chemotherapeutic, vinorelbine, as a single agent [114]. The combined regimen of pembrolizumab plus AR will be evaluated in a phase 1/2 trial (NCT03126630) that is recruiting only MSLN-positive patients. A phase I study (NCT02798536) is currently active to assess a novel low-immunogenic anti-MSLN recombinant immunotoxin, RG778/LMB-100 [115], composed of a human single-chain variable fragment (scFv)-targeting moiety directed against MSLN linked to Pseudomonas exotoxin A (PE). The phase I trial NCT01675765 evaluated the sequential administration of the cancer vaccine CRS-207, an attenuated form of Listeria monocytogenes expressing MSLN, with or without cyclophosphamide followed by consolidation CT, to stimulate an innate and adaptive immunity against MSLN-expressing cells. The cyclophosphamide arm showed acceptable toxicity and a DCR of 89%, a PR of 54%, an SD of 29%, and a median PFS and OS of 7.5 and 14.7 months, respectively [116].

The success of advanced cell-based therapies, e.g., Chimeric Antigen Receptor-transduced T cells (CAR-T) in hematological tumors, awoke interest as well for MPM [117]. CAR-T-cell receptors directed against MSLN are being investigated in several phase I clinical trials. The critical issues in Adoptive Cell Therapy (ACT) and CAR-T treatment are the safety profile and the degree of off-tumor toxicity. Intravenous or intra-tumor administration of MSLN-CAR-T cells (NCT01355965) [118] obtained by T-cell electroporation with encoding mRNA to
achieve transient expression resulted in moderate responses and low toxicity [119]. A phase I study (NCT02414269) drawing on preclinical results in orthotopic mouse MPM models [120,121] is ongoing to test the MSLN-CAR-T cells in multi-treated MPM patients. Preliminary results presented at the AACR [Abstract CT036, [122]] and ASCO [Abstract 2511, [123]] meetings this year have shown an ORR and DCR of 36.8 and 57.8%, respectively, in a cohort treated off protocol in combination with pembrolizumab.

Fibroblast activation protein (FAP) is another interesting target expressed by all MPM subtypes and by cancer-associated fibroblasts (CAFs) and exploited by FAP-targeted CAR-T cells in an ongoing phase I trial (NCT01722149) [124] Preliminary results presented at the ESMO congress this year showed a good tolerance of treatment and persistence of CAR-T cells [125].

CD26 is a receptor overexpressed by all MPM histotypes and involved in immune regulation, T-cell activation, and the malignant potential of several cancers [126,127]. YS110 is a humanized mAb targeting CD26 that is currently under investigation in a phase I clinical trial (NCT03177668) in MPM patients. Preliminary results show that 50% (13/26) of patients achieved SD, with a median PFS of 43 days [128,129].

**Discussion**

Despite amazing efforts devoted to understanding and treating MPM better (Figure 1 and Table 1), clinical practice has not changed over the past decades, and CT remains the only standard option. Anti-angiogenic therapies and also ICIs that showed impressive clinical responses in other solid malignancies have little impact on survival in MPM as single agents, while ICI combination efficiency comes at the cost of relevant toxicities. The hopes for patients with MPM are, therefore, innovative therapies such as oncoviral, TTFields, TargomiRs, and CAR therapies in combination with anti-PD-1 ICIs that have shown good preliminary efficacy, although the results need confirmation in larger trials.
Figure 1: Current and innovative clinical approaches for MPM. Different segments represent MPM standard therapies (light brown), MPM non-specific target-based therapies (brown), and MPM surface antigen-dependent therapies (orange). inh., inhibitor; DCV, dendritic cell vaccination; WT1, Wilms’ Tumor Antigen; CAR, chimeric antigen receptor; IL-2, interleukin-2; TILs, tumor-infiltrating lymphocytes; MSLN, mesothelin; FAP, fibroblast activation protein; CAFs, cancer-associated fibroblasts; PE, Pseudomonas exotoxin A.
Table 1: Overview of MPM clinical trials.

| Reference | Clinical trial code | Aymunonym | Type of study | OS (months) | PFS (months) | ORR (%) | DCR (%) | Result or status |
|-----------|---------------------|------------|--------------|-------------|-------------|---------|---------|-----------------|
| van Zandwijk et al. (2013) | NCT0239198 | MemOwhat | I | SGC + chemo | 56 | 10 | 45 | 70 | Poor (primary endpoint: MTD and DLT) |
| Gershenwald et al. (2015) | NCT00571569 | STS/LAM | II | TTX alone + CT | 18.2 | 7.8 | 40 | 52 | Poor (primary endpoint: MTX and DLT) |
| Stennert et al. (2017) | NCT02118914 | IMMUNE | I | JAX + CT | 21.5 | 25 | 65 | Poor (primary endpoint: safety) |
| Gals et al. (2015) | NCT01330658 | AIO-502 | III | AIO-502 + cardiac + gen. | 2.4 | 62 | Poor (primary endpoint: safety and tolerability) |
| Dawson et al. (2015) | NCT02171818 | NCI | II | IFL + CT | 15.5 | NE | Poor (primary endpoint: safety and tolerability) |
| van Zandwijk et al. (2015) | NCT0259188 | MemOwhat | I | SGC + chemo | 56 | 10 | 45 | 70 | Poor (primary endpoint: MTD and DLT) |
| van Zandwijk et al. (2016) | NCT02303892 | MPMX | III | PEM + chemo + radiation | 18.2 | 7.8 | 40 | 52 | Poor (primary endpoint: MTX and DLT) |
| Schiller et al. (2014) | NCT01421232 | MPMX | III | PEM + chemo + radiation | 18.2 | 7.8 | 40 | 52 | Poor (primary endpoint: MTX and DLT) |
| Gals et al. (2015) | NCT01330658 | AIO-502 | III | AIO-502 + cardiac + gen. | 2.4 | 62 | Poor (primary endpoint: safety and tolerability) |
| Dawson et al. (2015) | NCT02171818 | NCI | II | IFL + CT | 15.5 | NE | Poor (primary endpoint: safety and tolerability) |
| van Zandwijk et al. (2015) | NCT0259188 | MemOwhat | I | SGC + chemo | 56 | 10 | 45 | 70 | Poor (primary endpoint: MTD and DLT) |

**ANTI-MICELAR IMMUNOTHERAPY**

- Hassen et al. (2015) | NCT0738562 | Ateludsm + CT | 14.8 | 6 | 1 | 1 | Poor (primary endpoint: number of patients T cell counts and reg T cells in the blood of all patients) |
- Blumenschein et al. (2016) | NCT10438512 | AR | NE | 31 | 30 | Poor (primary endpoint: total and interim endpoints profile) |
- André et al. (2018) | NCT15503630 | AR | NE | 31 | 30 | Poor (primary endpoint: total and interim endpoints profile) |
- Hassen et al. (2015) | NCT0738562 | Ateludsm + CT | 14.8 | 6 | 1 | 1 | Poor (primary endpoint: number of patients T cell counts and reg T cells in the blood of all patients) |
- Blumenschein et al. (2016) | NCT10438512 | AR | NE | 31 | 30 | Poor (primary endpoint: total and interim endpoints profile) |
- André et al. (2018) | NCT15503630 | AR | NE | 31 | 30 | Poor (primary endpoint: total and interim endpoints profile) |

**NK/CD38/CD16 IMMUNOTHERAPY**

- Cappel et al. (2018) | NCT10731439 | MAPI + CAR-T | NE | NE | Poor (primary endpoint: safety) |
- Angelki et al. (2018) | NCT10731439 | MAPI + CAR-T | NE | NE | Poor (primary endpoint: safety) |
References

1. Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA A Cancer J Clin. 2019; 69: 402–429.

2. Andujar P, Lacourt A, Brochard P, Paire JC, Jaurand MC, et al. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles. J Toxicol Environ Health B Crit Rev. 2016; 19: 151–172.

3. Henley SJ, Larson TC, Wu M, Antao VCS, Lewis M, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health. 2013; 19: 1–10.

4. Yap TA, Aerts JG, Popat S, Fennel DA. Novel insights into mesothelioma biology and implications for therapy. Nature Reviews Cancer. 2017; 17: 475–488.

5. Sato T, Sekido Y. NF2/Merlin inactivation and potential therapeutic targets in mesothelioma. Int J Mol Sci. 2018; 19: 988–918.

6. Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, et al. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol. 2008; 3: 499–504.

7. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 2636–2644.

8. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26: v31–39.

9. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010; 35: 479–495.

10. van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, et al. Guidelines for the diagnosis and treatment of
malignant pleural mesothelioma. J Thorac Dis. 2013; 5: E254–307.

11. Lang-Lazdunski L, Bille A, Lal R, Cane P, McLean E, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol. 2012; 7: 737–743.

12. Sugarbaker DJ, Richards WG, Bueno R. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg. 2014; 260: 577–580. discussion: 580–582.

13. Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery MARS; randomised feasibility study. Lancet Oncol. 2011; 12: 763–772.

14. Friedberg JS, Simone CB, Culligan MJ, Barsky AR, Doucette A, et al. Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Ann Thorac Surg. 2017; 103: 912–919.

15. Zhao ZY, Zhao SS, Ren M, Liu ZL, Li Z, et al. Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis. Oncotarget. 2017; 8: 100640–100647.

16. Lang-Lazdunski L, Bille A, Belcher E, Cane P, Landau D, et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2011; 6: 1746–1752.

17. Opitz I, Lauk O, Meerang M, Jetter A, Aeschlimann B, et al. Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma - a phase I trial. J Thorac Cardiovasc Surg. 2019; 159: 330–340.e4.

18. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and
radiation for malignant pleural mesothelioma. J Clin Oncol. 2009; 27: 3007–3013.

19. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001; 122: 788–795.

20. Cho BC, Feld R, Leighl N, Opitz I, Anraku M, et al. A feasibility study evaluating surgery for mesothelioma after radiation therapy: the “SMART” approach for resectable malignant pleural mesothelioma. J Thorac Oncol. 2014; 9: 397–402.

21. de Perrot M, Feld R, Leighl NB, Hope A, Waddell TK, et al. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2016; 151: 468–473.

22. Nelson DB, Rice DC, Mitchell KG, Tsao AS, Gomez DR, et al. Return to intended oncologic treatment after surgery for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2019; 158: 924–929.

23. Clive AO, Taylor H, Dobson L, Wilson P, de Winton E, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma SMART,: a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016; 17: 1094–1104.

24. Bayman N, Appel W, Ashcroft L, Baldwin DR, Bates A, et al. Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase III randomized trial. J Clin Oncol. 2019; 37: 1200–1208.

25. Kindler HL, Ismailia N, Armato SG, Bueno R, Hesdorffer M, et al. Treatment of malignant pleural mesothelioma: ASCO clinical practice guidelines. JCO. 2018; 36: 1343–1373.

26. Minatel E, Trovo M, Bearz A, Di Maso M, Baresic T, et al. Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors. Int J Radiat Oncol Biol Phys. 2015; 93: 606–613.
27. Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy IMPRINT; as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol. 2016; 34: 2761–278.

28. Rosenzweig KE, Zauderer MG, Laser B, Krug LM, Yorke E, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol. Phys. 2012; 83: 1278–1283.

29. Pan HY, Jiang S, Sutton J, Liao Z, Chance WW, et al. Early experience with intensity modulated proton therapy for lung-intact mesothelioma: a case series. Pract Radiat Oncol. 2015; 5: e345–353.

30. Dumane VA, Rimner A, Yorke ED, Rosenzweig KE. Volumetric-modulated arc therapy for malignant pleural mesothelioma after pleurectomy/decortication. Appl Rad Oncol. 2016; 5: 28–37.

31. Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, et al. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012; 78: 76–80.

32. Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol. 2011; 6: 1938–1945.

33. Laurie SA, Hao D, Leighl NB, Goffin J, Khomani A, et al. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: the Ontario Clinical Oncology Group. Lung Cancer. 2017; 104: 65–69.

34. Laurie SA, Gupta A, Chu Q, Lee CW, Morzycki W, et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group. J Thorac Oncol. 2011; 6: 1950–1954.

35. Nowak AK, Millward MJ, Creaney J, Francis RJ, Hasani A, et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol. 2012; 7: 1449–1456.

36. Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer. 2005; 48: 291–296.
37. Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, et al. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B CALGB 30107; Lung Cancer. 2012; 76: 393–396.
38. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387: 1405–1414.
39. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borgiaee H, et al. NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016. J Natl Compr Canc Netw. 2016; 14: 825–836.
40. Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, et al. Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma SWOG S0905; J Thorac Oncol. 2017; 12: 1299–1308.
41. Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, et al. Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naïve patients with unresectable malignant pleural mesothelioma SWOG S0905; J Clin Oncol. 2019; 37: JCO1900269.
42. Grosso F, Steele N, Novello S, Nowak AK, Popat S, et al. Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial. J Clin Oncol. 2017; 35: 3591–3600.
43. Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma LUME-Meso;: a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019; 7: 569–580.
44. Buikhuisen WA, Scharpfenecker M, Griffioen AW, Korse CM, van Tinteren H, et al. A randomized phase 2 study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes. J Thorac Oncol. 2016; 11: 758–768.
45. Dubey S, Jänne PA, Krug L, Pang H, Wang X, et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010; 5: 1655–1661.

46. Papa S, Popat S, Shah R, Prevost AT, Lal R, et al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol. 2013; 8: 783–787.

47. van Brummelen EMJ, Levchenko E, Dómíne M, Fennell DA, Kindler HL, et al. A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Invest New Drugs. 2019; 17: 475–411.

48. Locke M, Ghazaly E, Freitas MO, Mitsinga M, Lattanzio L, et al. Inhibition of the polyamine synthesis pathway is synthetically lethal with loss of argininosuccinate synthase 1. Cell Rep. 2016; 16: 1604–1613.

49. Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, et al. Phase I dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with arginino-succinate synthetase 1-deficient thoracic cancers. J Clin Oncol. 2017; 35: 1778–1785.

50. Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue A, et al. Tumour suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci USA. 2014; 111: 285–290.

51. Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, et al. BAP1 regulates IP3R3-mediated Ca2+; flux to mitochondria suppressing cell transformation. Nature. 2017; 546: 549–553.

52. Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, et al. BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment. Int J Mol Sci. 2019; 20: 429–413.

53. Kumar N, Alrifai D, Kolluri KK, Sage EK, Ishii Y, et al. Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma. Lung Cancer. 2019; 127: 164–166.
54. Testa JR, Cheung M, Pei J, Below JE, Tan Y, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011; 43: 1022–1025.
55. Betti M, Aspesi A, Biasi A, Casalone E, Ferrante D, et al. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma. Cancer Lett. 2016; 378: 120–130.
56. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011; 48: 856–859.
57. Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci USA. 2019; 116: 9008–9013.
58. Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, et al. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother Pharmacol. 2017; 80: 861–867.
59. LaFave LM, Beguelin W, Koche R, Teater M, Spitzer B, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015; 21: 1344–1349.
60. Marchesi I, Bagella L. Targeting enhancer of zeste homolog 2 as a promising strategy for cancer treatment. World J Clin Oncol. 2016; 7: 135.
61. Zauderer MG, Szlosarek P, Le Moulec S, Popat S, Taylor P, et al. Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory R/R; malignant mesothelioma MM; with BAP1 inactivation. JCO. 2018; 36: 8515.
62. Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015; 146: 132–149.
63. Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumours. Ann Oncol. 2016; 27: 2268–2274.
64. Fennell DA, Baas P, Taylor P, Nowak A, Gilligan D, et al. Maintenance defactinib versus placebo after first-line
chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND—a double-blind, randomized, phase II study. JCO. 2019; 37: 790–798.

65. Chee SJ, Lopez M, Mellows T, Gankande S, Moutasim KA, et al. Evaluating the effect of immune cells on the outcome of patients with mesothelioma. Br J Cancer. 2017; 117: 1341–1348.

66. Ye L, Ma S, Robinson BW, Creaney J. Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine. Expert Rev Respir Med. 2019; 13: 181–192.

67. Moser JC, Peikert T, Roden AC, Midthun DE, Mansfield AS. Spontaneous regression of malignant pleural mesothelioma in a patient with new-onset inflammatory arthropathy. Ann Am Thorac Soc. 2015; 12: 1416–1417.

68. Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma–possible immunological mechanism. Lung Cancer. 2001; 32: 197–201.

69. Krishnan S, Bakker E, Lee C, Kissick HT, Ireland DJ, et al. Successful combined intratumoural immunotherapy of established murine mesotheliomas requires B-cell involvement. J Interferon Cytokine Res. 2015; 35: 100–107.

70. Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L, et al. Impact of tumour-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2008; 135: 823–839.

71. Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, et al. CD8+ tumour- infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010; 59: 1543–1549.

72. Gibbons Johnson RM, Dong H. Functional expression of programmed death-ligand 1 B7-H1; by immune cells and tumour cells. Front Immunol. 2017; 8: 961.

73. Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014; 9: 1036–1040.
74. Terra SBSP, Mansfield AS, Dong H, Peikert T, Roden AC. Temporal and spatial heterogeneity of programmed cell death 1-ligand 1 expression in malignant mesothelioma. Oncoimmunology. 2017; 6: e1356146.
75. Sepesi B, IconTeam, Heymach J, Sharma P, Allison J, et al. OA20.06 prospective immunogenomic profiling of non-small cell lung cancer - The ICON Project. J Thorac Oncol. 2017; 12: S324–325.
76. Balar AV, Weber J. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017; 66: 551–564.
77. Lievense LA, Sterman DH, Cornelissen R, Aerts JG. Checkpoint blockade in lung cancer and mesothelioma. Am J Respir Crit Care Med. 2017; 196: 274–282.
78. Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumours: opportunities and challenges. Immunotherapy. 2016; 8: 821–837.
79. Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013; 14: 1104–1111.
80. Maio M, Scherpereel A, Calabrò L, Aerts J, Cedres Perez S, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma DETERMINE-2: a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017; 18: 1261–1273.
81. Quispel-Janssen J, Zago G, Schouten R, Buikhuisen W, Monkhorst K, et al. OA13.01 a phase II study of nivolumab in malignant pleural mesothelioma NivoMes: with translational research TR; biopies. J Thorac Oncol. 2017; 12: S292–293.
82. Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma MERIT-. Clin Cancer Res. 2019; 25: 5485–5492.
83. Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients
with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials. 2018; 19: 233.

84. Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma KEYNOTE-028;: preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017; 18: 623–630.

85. Desai A, Karrison T, Rose B, Tan Y, Hill B, et al. OA08.03 phase II trial of pembrolizumab NCT02399371; in previously-treated malignant mesothelioma MM;: final analysis. J Thorac Oncol. 2018; 13: S339.

86. Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, et al. Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol. 2018; 13: 1784–1791.

87. Popat S, Curioni-Fontecedro A, Polydoropoulou V, Shah R, O'Brien M, et al. LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab P; vs single agent chemotherapy CT; for advanced pre-treated malignant pleural mesothelioma MPM;: results from the european thoracic oncology platform (ETOP 9–15) PROMISE-meso trial. Ann Oncol. 2019; 30: v931.

88. Angevin E, Bauer TM, Ellis CE, Gan H, Hall R, et al. Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors. Cancer Res. 2017; 77: CT039.

89. Scherpereel A, Mazieres J, Greillier L, Dô P, Bylicki O, et al. Second- or third-line nivolumab Nivo; versus nivo plus ipilimumab Ipi, in malignant pleural mesothelioma MPM;: results of the IFCT-1501 MAPS2 randomized phase II trial. JCO. 2017; 35: LBA8507.

90. Zalcman G, Peters S, Mansfield AS, Jahan TM, Popat S, et al. Checkmate 743: A phase 3, randomized, open-label trial of nivolumab nivo; plus ipilimumab ipi; vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma. JCO. 2017; 35: TPS8581.

91. Calabrò L, Morra A, Giannarelli D, Amato G, D'Incecco A, et al. Tremelimumab in combination with durvalumab in
first or second-line mesothelioma patients: safety analysis from the phase II NIBIT-MESO-1 study. Lancet Respir Med. 2018; 6: 451–460.

92. Chung HJ, Choi YE, Kim ES, Han YH, Park MJ, et al. miR-29b attenuates tumourigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2. Oncotarget. 2015; 6: 18429–18444.

93. Yang L, Li C, Liang F, Fan Y, Zhang S. MiRNA-155 promotes proliferation by targeting caudal-type homeobox 1 CDX1; in glioma cells. Biomed Pharmacother. 2017; 95: 1759–1764.

94. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008; 133: 217–222.

95. Reid G, Pel Me, Kirschner MB, Cheng YY, Mugridge N, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013; 24: 3128–3135.

96. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell. 2007; 11: 431–445.

97. van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017; 18: 1386–1396.

98. Weinberg U, Munster M, Gotlib K, Schneiderman RS, Porat Y, et al. The combined treatment of 150 kHz tumor treating fields TTFields; and cisplatin or pemetrexed inhibits mesothelioma cells in vitro and in vivo. JCO. 2019; 37: e20069.

99. Ceresoli G, Aerts J, Madrzak J, Dziadziuszko R, Ramlau R, et al. MA12.06 STELLAR - final results of a phase 2 trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma. J Thorac Oncol. 2018; 13: S397–398.

100. Sterman DH, Haas A, Moon E, Recio A, Schwed D, et al. A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med. 2011; 184: 1395–1399.
101. Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, et al. Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFNα combined with chemotherapy. Clin Cancer Res. 2016; 22: 3791–3800.

102. Goto Y, Ohe Y, Kuribayashi K, Nakano T, Okada M, et al. P2.06–11 a phase I/II study of intrapleural Ad-SGE-REIC administration in patients with refractory malignant pleural mesothelioma. J Thorac Oncol. 2018; 13: S746.

103. Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, , et al. Use of a “replication-restricted” herpes virus to treat experimental human malignant mesothelioma. Cancer Res. 1997; 57: 466–471.

104. Danson S, Woll P, Edwards J, Blyth K, Fisher P, et al. 366PDOncolytic herpesvirus therapy for mesothelioma: a phase I/IIa trial of intrapleural administration of HSV1716 NCT01721018;. Annonc. 2017; 28: v122–141.

105. Pease DF, Kratzke RA. Oncolytic viral therapy for mesothelioma. Front Oncol. 2017; 7: 525–515.

106. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12: 265–277.

107. Cornelissen R, Hegmans JP, Maat AP, Kaijen-Lambers ME, Bezemer K, et al. Extended tumour control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med. 2016; 193: 1023–1031.

108. Belderbos RA, Baas P, Berardi R, Cornelissen R, Fennell DA, et al. A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate MesoPher; in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma DENIM; trial. Transl Lung Cancer Res. 2019; 8: 280–285.

109. Berneman ZN, Van de Velde AL, Willemen Y, Anguille S, Saevels K, et al. Vaccination with WT1 mRNA-electroporated dendritic cells: report of clinical outcome in 66 cancer patients. Blood. 2014; 124: 310.

110. Doherty M, Leighl NB, Feld R, Bradbury PA, Wang L, et al. Phase I/II study of tumour-infiltrating lymphocyte TIL;
infusion and low-dose interleukin-2 IL-2; in patients with advanced malignant pleural mesothelioma MPM;. JCO. 2015; 33: TPS7586.

111. Lv J, Li P. Mesothelin as a biomarker for targeted therapy. Biomark Res. 2019; 7: 18.

112. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014; 20: 5927–5936.

113. Blumenschein GR, Hassan R, Moore KN, Santin A, Kindler HL, et al. Phase I study of anti-mesothelin antibody-drug conjugate anetumab ravtansine AR;. J Clin Oncol. 2016; 34: abstr 2509.

114. Kindler HL, Novello S, Fennell D, Blumenschein G, Bearz A, et al. OA 02.01 randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma. J Thorac Oncol. 2017; 12: S1746.

115. Zhang J, Khanna S, Jiang Q, Alewine C, Miettinen M, et al. Efficacy of anti-mesothelin immunotoxin RG7787 plus Nab-paclitaxel against mesothelioma patient-derived xenografts and mesothelin as a biomarker of tumor response. Clin Cancer Res. 2017; 23: 1564–1574.

116. Hassan R, Alley E, Kindler H, Antonia S, Jahan T, et al. Live-attenuated, Listeria monocytogenes expressing mesothelin CRS-207; with chemotherapy for treatment of malignant pleural mesothelioma. Clin Cancer Res. 2019; 25: 5787.

117. Zeltsman M, Dozier J, McGee E, Ngai D, Adusumilli PS. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma. Transl Res. 2017; 187: 1–10.

118. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumour. Cancer Res. 2010; 70: 9053–9061.

119. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, et al. Mesothelin-specific chimeric antigen receptor
mRNA-engineered T cells induce anti-tumour activity in solid malignancies. Cancer Immunol Res. 2014; 2: 112–120.

120. Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumour immunity. Sci Transl Med. 2014; 6: 261ra151.

121. Servais EL, Suzuki K, Colovos C, Rodriguez L, Sima C, et al. An in vivo platform for tumor biomarker assessment. PLoS ONE. 2011; 6: e26722.

122. Adusumilli PS, Zauderer MG, Rusch VW, O’Cearbhaill RE, Zhu A, et al. Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. Cancer Res. 2019; 79: CT036.

123. Adusumilli PS, Zauderer GM, Rusch VW, O’Cearbhaill RE, Zhu A, et al. Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent. JCO. 2019; 37: 2511.

124. Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific redirected T cells. J Transl Med. 2013; 11: 187.

125. Curioni A, Britschgi C, Hiltbrunner S, Bankel L, Gulati P, et al. 1226PA phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells. Annonc. 2019; 30: v501.

126. Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, et al. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res. 2007; 13: 4191–4200.

127. Dang NH, Torimoto Y, Schlossman SF, Morimoto C. Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family. J Exp Med. 1990; 172: 649–652.

128. Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, et al. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced
CD26-expressing cancers. Br J Cancer. 2017; 116: 1126–1134.
129. Nakano T, Kuribayashi K, Mikami K. Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil. Expert Rev Anticancer Ther. 2016; 16: 1097–109.